Intro Protocol
The Intro Protocol is your entry point into the IVUSE system. Semaglutide is a GLP-1 receptor agonist with one of the most extensive clinical track records in medical weight management. Complete a 5-minute medical assessment, and if approved, your prescription ships directly to your door.
The 2-month program gives you enough time to see your body respond. The 3-month program allows for full dose escalation, which is where patients tend to see the most significant results.
100% of our surveyed patients said this was easier than past weight loss attempts. Zero said it was harder.
- Licensed physician consultation and prescription
- Semaglutide medication for the full program duration
- Syringes, alcohol swabs, and all injection supplies
- Ongoing medical support and dosage adjustments
- Free priority shipping (3-5 business days)
- Dosing guide and injection instructions
Subcutaneous injection. Stomach, thigh, or upper arm. Once per week, any time of day. Rotate your injection site.
Your physician will start you at a conservative dose and escalate based on your response. The 3-month program allows for the full escalation protocol.
Nausea, diarrhea, and decreased appetite are common during the first two to four weeks. This is your body adjusting. It passes.
Most patients report mild nausea in weeks one and two that resolves with continued use. Serious side effects are rare and monitored by your prescribing provider.
Semaglutide is a GLP-1 receptor agonist with one of the longest and most studied clinical track records in weight management. It has proven efficacy across a broad patient population.
For patients who want a reliable, well-documented starting point, semaglutide is the standard.
Patients new to GLP-1 therapy who want a well-documented starting point with proven, consistent results across a broad population.
- Single receptor target (GLP-1)
- Extensive long-term safety data
- Gradual, steady weight loss
- Well-tolerated at lower doses
Patients seeking the most aggressive clinical approach, or those who have plateaued on single-action GLP-1 medications and want a stronger mechanism.
- Dual receptor target (GLP-1 + GIP)
- Potentially greater total weight loss
- Enhanced metabolic response
- Most advanced mechanism available
BUILD YOUR PROTOCOL
Duration: 2 months
Duration: 3 months
Duration: 5 months
Disclaimer and Transparency
Important Information About Compounded Injectables
- Compounded medications are not reviewed or approved by the FDA and do not undergo the same pre-market evaluation as FDA-approved drugs.
- IVUSE peptide injections are prepared using peptide ingredients by FDA-registered, U.S.-licensed 503A & 503B compounding pharmacies, where available and clinically appropriate.
- Availability and formulation may vary based on state regulations, evolving clinical guidance, and pharmacy partners.
All prescriptions, treatment decisions, and care plans are made independently by licensed healthcare providers using their professional judgment. Images and product depictions are for illustration only; actual packaging and supplies may vary.
*If you are interested in a prescription product, IVUSE will coordinate a telehealth visit with a licensed medical provider who will determine whether you are an appropriate candidate based on your health profile and current standards of care. If approved, a prescription will be issued and filled by one of our partner pharmacies. All prescriptions are subject to provider discretion and clinical appropriateness.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. All information provided here is for educational purposes only and does not replace personalized medical advice from a qualified healthcare professional.
Stop the medication and contact your provider if you experience persistent or concerning symptoms. Seek immediate medical care if you develop signs of a severe allergic reaction (such as hives, facial swelling, or difficulty breathing) or any rapidly worsening symptom.
